However, our study revealed that the effect of ICI treatment does not neutralize the short duration of response to EGFR-TKIs, suggesting the importance of long-term response to EGFR-TKIs in terms of survival benefits in patients with EGFR-mutant lung cancer. This evidence concerns the gene EGFR and lung carcinoma.